PD-1/PD-L1抑制剂诱导的低血症:使用FAERS数据库进行现实世界的药监测分析
Chao Tao1,2, Bingyao Liu3, Yan Dai1
1Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
编程细胞死亡蛋白1 (PD-1) 和PD-1连接物1 (PD-L1) 抑制剂可以导致低血,低水平. 这项研究分析了对尼沃卢马布,潘布罗利祖马布和阿特佐利祖马布的不良事件报告和确认的低血信号.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 在癌症治疗中,PD-1/PD-L1抑制剂的使用越来越多.
- 低血症被确定为一个显著的不良事件.
- 需要对这些免疫疗法进行强有力的安全监测.
研究的目的:
- 调查PD-1/PD-L1抑制剂与低血的相关性.
- 使用药监数据量化风险信号.
- 为临床管理和风险减轻策略提供信息.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据库 (Q1-2004至Q2-2024) 的分析.
- 使用四种统计方法 (ROR,PRR, BCNN,MGPS) 进行不成比例分析.
- 对尼沃卢马布,潘布罗利祖马布和阿特佐利祖马布的低血症信号的评估.
主要成果:
- 确定了1339起涉及1274名患者的低血症报告.
- 对于尼沃卢马布,潘布罗利祖马布和阿特佐利祖马布,一致的阳性低血症信号.
- 低血症主要影响45岁以上的男性,平均发病时间因药物和人口统计学因素而异.
结论:
- 证实了PD-1/PD-L1抑制剂和低血的相关性.
- 强调在接受这些治疗的患者中监测水平的重要性.
- 提供数据来增强PD-1/PD-L1抑制剂治疗的风险管理策略.
更多相关视频
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Peritoneal Dialysis III: Nursing Management
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
